Literature DB >> 28455582

Glutathione S-transferases deletions may act as prognosis and therapeutic markers in breast cancer.

Clodoaldo Zago Campos1,2, Roberta Losi Guembarovski3, Carlos Eduardo Coral de Oliveira4, Bruna Karina Banin Hirata4, Glauco Akelinghton Freire Vitiello4, Flávia Luísa Dias4, Carlos Hiroji Hiroki4, Maria Angelica Ehara Watanabe5, Tânia Longo Mazzuco6.   

Abstract

Breast cancer (BC) is the main worldwide neoplasia in women. The metabolic balance between xenobiotic absorption and elimination rates plays an important role in preventing DNA damage and, consequently, tumor development. The glutathione S-transferases (GSTs), such as GSTM1 and GSTT1, and the NAD(P)H quinone oxidoreductase are important enzymes involved in phase II detoxification reactions. Deletions in GSTM1 and GSTT1, and single-nucleotide polymorphism (SNP) in NQO1 (rs1800655) have been investigated in cancer context, revealing conflicting results. The present study analyzed these genetic polymorphisms in 121 BC patients and 151 BC-free controls in order to verify if they could act as susceptibility modifiers and/or prognostic factors. Binary logistic regressions adjusted by age were performed to assess associations between allelic variants and interactions in polymorphisms combination with BC susceptibility, but no significant association was found. Genotypes distribution was also compared between BC subtypes, but no significant difference was observed (p > 0.05). GSTM1 deletion was significantly associated with histopathological grade, with a greater proportion of patients presenting grade III tumors (p = 0.007). Univariate analysis identified tumor size as the only clinicopathological parameter potentially associated with recurrence risk in patients that received adjuvant chemotherapy (p < 0.1). Thus, logistic regression analysis adjusted by tumor size revealed a positive association between GSTT1 deletion and recurrence risk in general BC (OR 4.25; p = 0.04), while GSTM1 was negatively associated with recurrence risk in ER/PR+HER2- samples (OR 0.07; p = 0.03). In conclusion, the present study indicated that GSTT1 deletion was associated with increased recurrence risk, while GSTM1 correlated with worst prognosis parameters at diagnosis, but was negatively associated with recurrence risk in luminal subtype samples.

Entities:  

Keywords:  Breast cancer; GSTM1; GSTT1; Genetic polymorphisms; Prognosis; Recurrence risk

Mesh:

Substances:

Year:  2017        PMID: 28455582     DOI: 10.1007/s10238-017-0461-6

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  34 in total

1.  Concluding remarks: symposium on Genetic Susceptibility to Environmental Toxicants.

Authors:  F F Kadlubar
Journal:  Mutat Res       Date:  2001-10-01       Impact factor: 2.433

Review 2.  GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGE review.

Authors:  S A Geisler; A F Olshan
Journal:  Am J Epidemiol       Date:  2001-07-15       Impact factor: 4.897

Review 3.  Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response.

Authors:  H Autrup
Journal:  Mutat Res       Date:  2000-01-03       Impact factor: 2.433

4.  Genetic composition of Brazilian population samples based on a set of twenty-eight ancestry informative SNPs.

Authors:  Tulio C Lins; Rodrigo G Vieira; Breno S Abreu; Dario Grattapaglia; Rinaldo W Pereira
Journal:  Am J Hum Biol       Date:  2010 Mar-Apr       Impact factor: 1.937

5.  Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma.

Authors:  Gong Yang; Xiao-Ou Shu; Zhi-Xian Ruan; Qiu-Yin Cai; Fan Jin; Yu-Tang Gao; Wei Zheng
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

6.  Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer.

Authors:  C B Ambrosone; C Sweeney; B F Coles; P A Thompson; G Y McClure; S Korourian; M Y Fares; A Stone; F F Kadlubar; L F Hutchins
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

Review 7.  The role of targeted therapy and biomarkers in breast cancer treatment.

Authors:  Alison T Stopeck; Ursa Brown-Glaberman; Hong Yuen Wong; Ben Ho Park; Sara E Barnato; William J Gradishar; Clifford A Hudis; Hope S Rugo
Journal:  Clin Exp Metastasis       Date:  2012-06-13       Impact factor: 5.150

8.  NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity.

Authors:  R D Traver; T Horikoshi; K D Danenberg; T H Stadlbauer; P V Danenberg; D Ross; N W Gibson
Journal:  Cancer Res       Date:  1992-02-15       Impact factor: 12.701

9.  Lack of association among polymorphic xenobiotic-metabolizing enzyme genotypes and the occurrence and progression of oral carcinoma in a Brazilian population.

Authors:  Roberta Losi-Guembarovski; Ilce Mara de Syllos Cólus; Rodrigo Paes De Menezes; Fernando Poliseli; Vivian Nappi Chaves; Hellen Kuasne; Andrei Leichsenring; Alda Losi Guembarovski; Benedito W Oliveira; Gyl Ramos; Teresa C S Cavalcanti; Lauro Toyshi Mizuno; Iglenir João Cavalli; Enilze Maria de Souza Fonseca Ribeiro
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

10.  GSTM1 enzyme concentration and enzyme activity in correlation to the genotype of detoxification enzymes in squamous cell carcinoma of the oral cavity.

Authors:  S Gronau; D Koenig-Greger; M Jerg; H Riechelmann
Journal:  Oral Dis       Date:  2003-03       Impact factor: 3.511

View more
  5 in total

1.  Effects of GSTT1 and GSTM1 polymorphisms in glutathione levels and breast cancer development in Brazilian patients.

Authors:  Marla Karine Amarante; Roberta Losi Guembarovski; Maria Angélica Ehara Watanabe; Carolina Panis; Letícia Madureira Pacholak; Rodrigo Kern; Stefania Tagliari de Oliveira; Leia Carolina Lúcio
Journal:  Mol Biol Rep       Date:  2021-01-16       Impact factor: 2.316

2.  Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients.

Authors:  Yue Zhao; Yimin Wang; Fudi Zhu; Jiayu Zhang; Xiao Ma; Dongwei Zhang
Journal:  Clin Exp Med       Date:  2020-01-24       Impact factor: 3.984

3.  Deletion and downregulation of MTAP contribute to the motility of esophageal squamous carcinoma cells.

Authors:  Xiao-Yu Cheng; Zou Liu; Li Shang; Hong-Qing Cai; Yu Zhang; Yan Cai; Xin Xu; Jia-Jie Hao; Ming-Rong Wang
Journal:  Onco Targets Ther       Date:  2017-12-11       Impact factor: 4.147

4.  GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer.

Authors:  Jian Zhang; Ying Wu; Xichun Hu; Biyun Wang; Leiping Wang; Sheng Zhang; Jun Cao; Zhonghua Wang
Journal:  Oncotarget       Date:  2017-11-14

Review 5.  Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases.

Authors:  Nerino Allocati; Michele Masulli; Carmine Di Ilio; Luca Federici
Journal:  Oncogenesis       Date:  2018-01-24       Impact factor: 7.485

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.